NCT02861534View on ClinicalTrials.gov

A Study of Vericiguat in Participants With Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-001)

PHASE3CompletedINTERVENTIONAL
Enrollment

5,050

Participants

Timeline

Start Date

September 20, 2016

Primary Completion Date

June 18, 2019

Study Completion Date

September 2, 2019

Conditions
Heart FailureChronic Heart Failure With Reduced Ejection Fraction
Interventions
DRUG

Vericiguat

2.5, 5.0, or 10.0 mg orally once daily

DRUG

Placebo for vericiguat

2.5, 5.0, or 10.0 mg orally once daily

Sponsors
All Listed Sponsors
collaborator

Bayer

INDUSTRY

collaborator

Canadian VIGOUR Centre

OTHER

collaborator

Duke Clinical Research Institute

OTHER

lead

Merck Sharp & Dohme LLC

INDUSTRY